Castle Biosciences (CSTL) EBIAT (2018 - 2025)
Historic EBIAT for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to -$501000.0.
- Castle Biosciences' EBIAT fell 12208.02% to -$501000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.2 million, marking a year-over-year decrease of 30141.56%. This contributed to the annual value of $18.2 million for FY2024, which is 13174.92% up from last year.
- As of Q3 2025, Castle Biosciences' EBIAT stood at -$501000.0, which was down 12208.02% from $4.5 million recorded in Q2 2025.
- Castle Biosciences' EBIAT's 5-year high stood at $9.6 million during Q4 2024, with a 5-year trough of -$29.2 million in Q1 2023.
- Its 5-year average for EBIAT is -$8.4 million, with a median of -$6.4 million in 2021.
- Per our database at Business Quant, Castle Biosciences' EBIAT tumbled by 103938.11% in 2023 and then skyrocketed by 47170.54% in 2024.
- Castle Biosciences' EBIAT (Quarter) stood at -$6.4 million in 2021, then tumbled by 220.65% to -$20.6 million in 2022, then skyrocketed by 87.49% to -$2.6 million in 2023, then soared by 471.71% to $9.6 million in 2024, then crashed by 105.22% to -$501000.0 in 2025.
- Its EBIAT was -$501000.0 in Q3 2025, compared to $4.5 million in Q2 2025 and -$25.8 million in Q1 2025.